Impact of metformin versus repaglinide on non-glycemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes

S.S. Lund; L. Tarnow; C.D.A. Stehouwer; C.G. Schalkwijk; T. Teerlink; J. Gram; K. Winther; M. Frandsen; U.M. Smidt; O. Pedersen; H.H. Parving; A.A. Vaag

doi:10.1530/EJE-07-0815

Impact of metformin versus repaglinide on non-glycemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes

S.S. Lund^*
, L. Tarnow
, C.D.A. Stehouwer
, C.G. Schalkwijk
, T. Teerlink
, J. Gram
, K. Winther
, M. Frandsen
, U.M. Smidt
, O. Pedersen
, H.H. Parving
, A.A. Vaag

^*Corresponding author for this work

CARIM - Cardiovascular Research Institute Maastricht

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Objective: In patients with type 2 diabetes mellitus (T2DM), biomarkers reflecting inflammation and endothelial dysfunction have been linked to cardiovascular disease (CVD biomarkers) and metabolic regulation. In T2DM patients, metformin and insulin secretagogues have demonstrated equal anti-hyperglycaemic potency. Here, we report the effect of metformin versus an insulin secretagogue, repaglinide, on CVD biomarkers in non-obese T2DM patients. Design and methods: Single-centre, double-masked, double-dummy, crossover study during 2x4 months involving 96 non-obese (body mass index

Original language	English
Pages (from-to)	631-41
Journal	European Journal of Endocrinology
Volume	158
DOIs	https://doi.org/10.1530/EJE-07-0815
Publication status	Published - 1 Jan 2008

Access to Document

10.1530/EJE-07-0815

Cite this

Lund, S. S., Tarnow, L., Stehouwer, C. D. A., Schalkwijk, C. G., Teerlink, T., Gram, J., Winther, K., Frandsen, M., Smidt, U. M., Pedersen, O., Parving, H. H., & Vaag, A. A. (2008). Impact of metformin versus repaglinide on non-glycemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. European Journal of Endocrinology, 158, 631-41. https://doi.org/10.1530/EJE-07-0815

@article{123228913f634cb193c64bd845a42a20,

title = "Impact of metformin versus repaglinide on non-glycemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes",

abstract = "Objective: In patients with type 2 diabetes mellitus (T2DM), biomarkers reflecting inflammation and endothelial dysfunction have been linked to cardiovascular disease (CVD biomarkers) and metabolic regulation. In T2DM patients, metformin and insulin secretagogues have demonstrated equal anti-hyperglycaemic potency. Here, we report the effect of metformin versus an insulin secretagogue, repaglinide, on CVD biomarkers in non-obese T2DM patients. Design and methods: Single-centre, double-masked, double-dummy, crossover study during 2x4 months involving 96 non-obese (body mass index ",

author = "S.S. Lund and L. Tarnow and C.D.A. Stehouwer and C.G. Schalkwijk and T. Teerlink and J. Gram and K. Winther and M. Frandsen and U.M. Smidt and O. Pedersen and H.H. Parving and A.A. Vaag",

year = "2008",

month = jan,

day = "1",

doi = "10.1530/EJE-07-0815",

language = "English",

volume = "158",

pages = "631--41",

journal = "European Journal of Endocrinology",

issn = "0804-4643",

publisher = "Oxford University Press",

}

Lund, SS, Tarnow, L, Stehouwer, CDA, Schalkwijk, CG, Teerlink, T, Gram, J, Winther, K, Frandsen, M, Smidt, UM, Pedersen, O, Parving, HH & Vaag, AA 2008, 'Impact of metformin versus repaglinide on non-glycemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes', European Journal of Endocrinology, vol. 158, pp. 631-41. https://doi.org/10.1530/EJE-07-0815

Impact of metformin versus repaglinide on non-glycemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. / Lund, S.S.; Tarnow, L.; Stehouwer, C.D.A. et al.
In: European Journal of Endocrinology, Vol. 158, 01.01.2008, p. 631-41.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Impact of metformin versus repaglinide on non-glycemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes

AU - Lund, S.S.

AU - Tarnow, L.

AU - Stehouwer, C.D.A.

AU - Schalkwijk, C.G.

AU - Teerlink, T.

AU - Gram, J.

AU - Winther, K.

AU - Frandsen, M.

AU - Smidt, U.M.

AU - Pedersen, O.

AU - Parving, H.H.

AU - Vaag, A.A.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Objective: In patients with type 2 diabetes mellitus (T2DM), biomarkers reflecting inflammation and endothelial dysfunction have been linked to cardiovascular disease (CVD biomarkers) and metabolic regulation. In T2DM patients, metformin and insulin secretagogues have demonstrated equal anti-hyperglycaemic potency. Here, we report the effect of metformin versus an insulin secretagogue, repaglinide, on CVD biomarkers in non-obese T2DM patients. Design and methods: Single-centre, double-masked, double-dummy, crossover study during 2x4 months involving 96 non-obese (body mass index

AB - Objective: In patients with type 2 diabetes mellitus (T2DM), biomarkers reflecting inflammation and endothelial dysfunction have been linked to cardiovascular disease (CVD biomarkers) and metabolic regulation. In T2DM patients, metformin and insulin secretagogues have demonstrated equal anti-hyperglycaemic potency. Here, we report the effect of metformin versus an insulin secretagogue, repaglinide, on CVD biomarkers in non-obese T2DM patients. Design and methods: Single-centre, double-masked, double-dummy, crossover study during 2x4 months involving 96 non-obese (body mass index

U2 - 10.1530/EJE-07-0815

DO - 10.1530/EJE-07-0815

M3 - Article

SN - 0804-4643

VL - 158

SP - 631

EP - 641

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

ER -

Impact of metformin versus repaglinide on non-glycemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes

Abstract

Access to Document

Fingerprint

Cite this